Labgenomics Co

Labgenomics Co Net Tangible Assets

The Net Tangible Assets of Labgenomics Co (084650.KQ) as of Nov 6, 2026 is 94.05 B KRW. In the previous year, Net Tangible Assets was 133.62 B KRW — a change of -29.62% (lower).

Net Tangible Assets

94.05 BKRW

YoY

-29.62%

Last updated:

Net Tangible Assets of Labgenomics Co is 2025 94.05 B KRW. Net Tangible Assets of Labgenomics Co was 2024 133.62 B KRW. It decreases by -29.62% lower compared to the previous year.

The Labgenomics Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
25.83 B KRW
Jan 1, 2019
26.75 B KRW
Jan 1, 2020
79.89 B KRW
Jan 1, 2021
156.98 B KRW
Jan 1, 2022
208.32 B KRW
Jan 1, 2023
151.74 B KRW
Jan 1, 2024
133.62 B KRW
Jan 1, 2025
94.05 B KRW
The Labgenomics Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
94.05 BKRW-29.62%
133.62 BKRW-11.94%
151.74 BKRW-27.16%
208.32 BKRW+32.71%
156.98 BKRW+96.49%
79.89 BKRW+198.65%
26.75 BKRW+3.57%
25.83 BKRW+63.56%
15.79 BKRW-5.95%
16.79 BKRW+5.41%
15.93 BKRW-8.16%
17.34 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Net Tangible Assets of Labgenomics Co is 94.05 B KRW in 2025.

Net Tangible Assets of Labgenomics Co changed from 133.62 B KRW to 94.05 B KRW, representing a -29.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labgenomics Co

All Key Metrics — Labgenomics Co